Activating Dormant Strongyloidiasis Secondary to COVID-19 Treatment

Abstract

The SARS-CoV-2 pandemic has grown into a major global concern with huge efforts to combat the spread. Exaggerated inflammatory response plays a major role in which was the rationale to use corticosteroids as a treatment option. However, multiple studies showed an association between of opportunistic and bacterial infections in patients under corticosteroid therapy. We report a case of a 76-year old patient diagnosed with COVID-19 pneumonia, treated with 10 days Dexamethasone and Remdesivir who presented with abdominal symptoms with eosinophilia. Biopsy and stool studies revealed strongyloides stercoralis larvae. The patient was treated with 2 doses of Ivermectin with significant clinical resolution. Clinician should have high clinical suspicion for Strongloydiasis in patients who have lived or visited Strongyloides stercoralis endemic areas and for patients with unexplained eosinophilia. Prompt treatment with Ivermectin is crucial for confirmed cases and should be also implemented empirical in high risk groups, where obtaining a diagnosis is unfeasible.

Keywords

Strongyloides stercoralis / Corticosteroids / Dexamethasone / SARS-CoV-2 / Immunosuppression

References

[1] Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020; 109: 102433. PMid:32113704. https://doi.org/10.1016/j.jaut.2020.102433

[2] Zhang C, Wu Z, Li JW, et al. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents. 2020; 55: 105954. PMid:32234467. https://doi.org/10.1016/j.ijantimicag.2020.105954

[3] Veronese N, Demurtas J, Yang L, et al. Use of corticosteroids in Coronavirus disease 2019 pneumonia: A systematic review of the literature. Front Med (Lausanne). 2020; 7. PMid:32391369. https://doi.org/10.3389/fmed.2020.00170

[4] The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with covid-19. N Engl J Med. 2021; 384: 693-704. PMid:32678530. https://doi.org/10.1056/NEJMoa2021436

[5] Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019- nCoV) in vitro. Cell Res. 2020; 30: 269-71. PMid:32020029. https://doi.org/10.1038/s41422-020-0282-0

[6] Frost MT, Jimenez-Solem E, Ankarfeldt MZ, et al. The Adaptive COVID-19 Treatment Trial-1 (ACTT-1) in a real-world population: a comparative observational study. Crit Care. 2020; 24: 677. PMid:33287853. https://doi.org/10.1186/s13054-020-03406-3

[7] Obata R, Maeda T, Rizk D, et al. Increased secondary infection in COVID-19 patients treated with steroids in New York city. Jpn J Infect Dis. 2021; 74: 307-15. PMid:33390434. https://doi.org/10.7883/yoken.JJID.2020.884

[8] Klein NC, Go CHU, Cunha BA. Infections associated with steroid use. Infect Dis Clin North Am. 2001; 15: 423-32. https://doi.org/10.1016/S0891-5520(05)70154-9

[9] Greaves D, Coggle S, Pollard C, et al. Strongyloides stercoralis infection. BMJ. 2013; 347: f4610. PMid:23900531. https://doi.org/10.1136/bmj.f4610

[10] Mafort TT, Reis LVT, Faria LF, et al. Alveolar hemorrhage secondary to infection by strongyloides stercoralis in immunosuppressed patient— case report. Am J Respir Crit Care Med. 2017; 195: A5586.

[11] Buonfrate D, Requena-Mendez A, Angheben A, et al. Severe strongyloidiasis: a systematic review of case reports. BMC Infect Dis. 2013; 13: 78. PMid:23394259. https://doi.org/10.1186/1471-2334-13-78

[12] Brotherton H, Usuf E, Nadjm B, et al. Dexamethasone for COVID- 19: data needed from randomised clinical trials in Africa. Lancet Glob Health. 2020; 8: e1125-6. https://doi.org/10.1016/S2214-109X(20)30318-1

[13] Mejia R, Nutman TB. Screening, prevention, and treatment for hyperinfection syndrome and disseminated infections caused by Strongyloides stercoralis. Curr Opin Infect Dis. 2012; 25: 458-63. PMid:22691685. https://doi.org/10.1097/QCO.0b013e3283551dbd

[14] Kassalik M, Mönkemüller K. Strongyloides stercoralis hyperinfection syndrome and disseminated disease. Gastroenterol Hepatol (N Y). 2011; 7: 766-8.

[15] Requena-Méndez A, Buonfrate D, Gomez-Junyent J, et al. Evidencebased guidelines for screening and management of strongyloidiasis in non-endemic countries. Am J Trop Med Hyg. 2017; 97: 645-52. PMid:28749768. https://doi.org/10.4269/ajtmh.16-0923

[16] Stauffer WM, Alpern JD, Walker PF. COVID-19 and dexamethasone: A potential strategy to avoid steroid-related Strongyloides hyperinfection: A potential strategy to avoid steroid-related Strongyloides hyperinfection. JAMA. 2020; 324: 623-4. PMid:32761166. https://doi.org/10.1001/jama.2020.13170

[17] Buonfrate D, Salas-Coronas J, Muñoz J, et al. Multiple-dose versus single-dose ivermectin for Strongyloides stercoralis infection (Strong Treat 1 to 4): a multicentre, open-label, phase 3, randomised controlled superiority trial. Lancet Infect Dis. 2019; 19: 1181-90. https://doi.org/10.1016/S1473-3099(19)30289-0

[18] CDC-Centers for Disease Control, Prevention. CDC - Strongyloides - resources for health professionals. 2010.

[19] Marchese V, Crosato V, Gulletta M, et al. Strongyloides infection manifested during immunosuppressive therapy for SARS-CoV-2 pneumonia. Infection. 2021; 49: 539-42. PMid:32910321. https://doi.org/10.1007/s15010-020-01522-4

[20] Lier AJ, Tuan JJ, DavisMW, et al. Case report: Disseminated strongyloidiasis in a patient with COVID-19. Am J Trop Med Hyg. 2020; 103: 1590-2. PMid:32830642. https://doi.org/10.4269/ajtmh.20-0699